Bolar Is Not a Blanket: Madras High Court on Vildagliptin API Exports
In the case of Novartis AG v. Venkata Narayana Active Ingredients Pvt. Ltd., the Madras High Court dealt with a familiar pharmaceutical patent question in a concrete factual…
Novartis
11 articles
Strategic Delay Costs Novartis Its Cross-Examination Rights
The Delhi High Court dismissed Novartis’s writ petitions, ruling it had waived cross-examination by opting for rebuttal evidence. The Controller’s orders were upheld, with the patent already revoked…
Revisiting Novartis versus Natco – Cancer drugs, divisional applications and patent validity
The Delhi High Court upheld the validity of Novartis’s Ceritinib patent against Natco’s challenge, addressing divisional application issues and allegations of suppression. The injunction against Natco remains in…
Novartis says No to Novarish
The Bombay High Court granted Novartis an injunction against Novarish Healthcare for trademark infringement and passing off. The court found the marks deceptively similar and protected Novartis's established…
Cancerous Battle: Novartis and NATCO clash over Eltrombopag
The Delhi High Court Division Bench set aside an injunction against Natco Pharma in the Novartis Eltrombopag patent dispute. The judgment provides key guidance on patent validity challenges…
Profiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary Patents
This post explores how drug manufacturers leverage secondary patents to manage the patent cliff and maintain exclusivity. A detailed analysis of Entresto’s patent timeline and Indian legal context…
Latest Patent & Design Updates – January 2022 – Part 1
The post analyses significant patent and design updates for January 2022, focusing on India’s WTO patent waiver request and RGNIIPM’s training initiative. It also highlights major international patent…
Latest Patent Cases in 2021 – Part 3
This article examines recent patent litigation before the Delhi High Court, highlighting cases involving Novartis and Sulphur Mills in 2021. It discusses key judicial findings on patent validity,…
Novartis Trademark JALRA to be acquired for 200 crores, Private Company Acquires .Org Registry and more
USV Pvt Ltd will acquire the JALRA trademark from Novartis for 200 crores as the patent for Vildagliptin expires. The bulletin also discusses major updates in domain name…
Novartis Case Review
The Supreme Court’s Novartis judgment clarified Section 3d and its application to pharmaceutical patents in India. It emphasised the need for enhanced therapeutic efficacy and outlined critical standards…